OUR RESPONSE TO THE SITUATION IN UKRAINE
We are deeply concerned about the tragic and shocking events continuing to unfold in Ukraine. We utterly condemn the military action and the harm and suffering it’s causing to people in Ukraine and beyond. As a global HIV company, our priority remains to work closely with GSK and our partners to do everything we can to support our colleagues and people living with HIV in Ukraine and across this region.
Through our partnerships with the UN-backed Medicines Patent Pool and Aurobindo, we have voluntary licensing agreements in place to enable generic manufacturers to supply low cost dolutegravir-based regimens to Ukraine as well as other countries in the area.
We have also donated more than 10,000 packs of anti-retroviral medicines to National HIV/AIDS programmes and NGO partners across 4 countries, to support people living with HIV in the region who have been impacted by the conflict. This includes a significant donation of paediatric Tivicay for children living with HIV in Ukraine, as well as donations of our medicines to support continued access to HIV treatment for displaced Ukrainian people in Poland, Russia and the Czech Republic.
We are also providing funding of more than £850,000 from Positive Action to 12 community-based organisations, supporting humanitarian response activities and continued delivery of care both within Ukraine and neighbouring EU countries.
Together with GSK, ViiV has additionally pledged £2 million via the Global Fund to help maintain HIV and TB testing and treatment for internally displaced people and unserved and underserved communities, who are vulnerable to treatment interruption. We have also supported relief efforts through partners on the ground, such as Save the Children, and contributed to GSK's £3 million donation to the Red Cross’s Ukraine Crisis work.
We’ll continue to review our response as the situation evolves to ensure we care for our colleagues and that we are continuing to do all that we can to support our partners and people living with HIV, wherever they are.
We fully support the measures taken by governments across the world to respond to these tragic events, including the implementation of sanctions.
For our corporate press office, email: Rachel Jaikaran
OR call +44 7823 523 755
For US-specific media enquiries, email: Audrey Abernathy
OR call +1 919 605 4521
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.